Benefit and risk of prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with chronic kidney disease: A nationwide cohort study.

MLA

Kim, Choongki, et al. “Benefit and Risk of Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation in Patients with Chronic Kidney Disease: A Nationwide Cohort Study.” Atherosclerosis, vol. 352, July 2022, pp. 69–75. EBSCOhost, https://doi.org/10.1016/j.atherosclerosis.2022.05.019.

APA

Kim, C., Choi, D.-W., Lee, S.-J., Suh, Y., Hong, S.-J., Ahn, C.-M., Kim, J.-S., Kim, B.-K., Ko, Y.-G., Choi, D., Park, E.-C., Jang, Y., Nam, C.-M., & Hong, M.-K. (2022). Benefit and risk of prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with chronic kidney disease: A nationwide cohort study. Atherosclerosis, 352, 69–75. https://doi.org/10.1016/j.atherosclerosis.2022.05.019

Chicago

Kim, Choongki, Dong-Woo Choi, Seung-Jun Lee, Yongsung Suh, Sung-Jin Hong, Chul-Min Ahn, Jung-Sun Kim, et al. 2022. “Benefit and Risk of Prolonged Dual Antiplatelet Therapy after Drug-Eluting Stent Implantation in Patients with Chronic Kidney Disease: A Nationwide Cohort Study.” Atherosclerosis 352 (July): 69–75. doi:10.1016/j.atherosclerosis.2022.05.019.